Post by alonzo07
 Tue, Oct 03 09:03 AM

Another day, another biotech shakers.  Biohaven pharmaceutical BVHVN reported yesterday that its Trigriluzole Phase 2/3 trial in spinocerebellar ataxia missed the primary endpoint, see full link: 

Stock price reaction reacted negatively on headline  MISSED primary endpoint, the good part in my opinion - trigriluzole did demonstrate a favorable safety and tolerability profile, with no drug-related serious adverse events and low discontinuation rates due to adverse events. Trigriluzole has shown absence of a negative food effect, optimized oral bioavailability and no pattern of clinically significant effects on liver function, presenting a profile that appears distinct from what is described for riluzole in its U.S. prescribing information.

#BHVN stock price dropped -28% but recovered most of its losses, #BHVN closed -4.87% from -28% intraday low.  Massive recovery on share price despite of multiple analysts downgrade on the data release, -> Needham $36 from $43;  MS $38 from $47;

Please share any feedbacks. :)

 Sun, Oct 08 00:38 AM

do you think it will be back again to 35? 32 friday's close. TY

 1 Replies